MedTrace Logo

Efficacy and Safety of AQX-1125 in IC/BPS

NCT01882543 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 69

Last updated 2017-09-05

Study results available
· View outcomes & findings →

Summary

The primary objective of this study is to evaluate the effect of 6 weeks of treatment with once daily administration of AQX-1125 compared to placebo on average daily pain in subjects with interstitial cystitis/bladder pain syndrome (IC/BPS), during and after treatment, using a standardized 11-point numerical rating scale (NRS) pain score recorded by electronic diary

Conditions

  • Interstitial Cystitis
  • Bladder Pain Syndrome

Interventions

DRUG

AQX-1125

Synthetic SHIP1 activator

DRUG

Placebo

Double blind placebo capsule

Sponsors & Collaborators

  • Aquinox Pharmaceuticals (Canada) Inc.

    lead INDUSTRY

Principal Investigators

  • Stephen B Shrewsbury, MD · Aquinox Pharmaceuticals (Canada) Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-06-30
Primary Completion
2015-06-30
Completion
2015-06-30

Countries

  • United States
  • Canada

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01882543 on ClinicalTrials.gov